Ascentage lists on NASDAQ as Odyssey, Sionna, Aardvark plot IPOs

Although some biotech investors don’t expect a wave of IPOs until the new year’s second half, a handful of companies are already lining up new listings on NASDAQ or in Hong Kong.

One oncology company already traded in Hong Kong made its debut on NASDAQ Friday. Ascentage Pharma Group International (HKEX:6855; NASDAQ:AAPG) became a dual-listed company upon pricing an offering that raised $126.4 million through the sale of 7.3 million ADSs at $17.25. The biotech’s BCR-ABL inhibitor Nerik olverembatinib is approved in China for chronic myeloid leukemia; Ascentage is aiming to submit an NDA to FDA for the drug next year...